This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 337 studies, archived under the term: "neuropsychological tests"

Click here to filter this large number of results.

Cognitive function in early clinical phase huntington disease after rivastigmine treatment

Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]

Detection of cognitive impairment and dementia using the animal fluency test: the DECIDE study

Objectives: To evaluate the performance of a one-minute screening test measured against a validated 10-minute screening test for mild cognitive impairment (MCI) in detecting CI in patients aged > or = 65 years with two or more vascular risk factors (VRF).; Methods: Patients (n=1523) aged 65 years or older without documented CI symptoms or dementia […]

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease

Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]

Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial

Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease

Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]

Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study

Context: Smoking is a possible risk factor for dementia, although its impact may have been underestimated in elderly populations because of the shorter life span of smokers.; Objective: To examine the association between smoking history and cognitive decline in the transition from midlife to old age.; Design: Cohort study.; Setting: The Whitehall II study. The […]

Validity and reliability of the Korean version of the AD8 informant interview (K-AD8) in dementia

The Alzheimer disease 8 (AD8) is a brief informant-based measure that distinguishes individuals with very mild dementia and mild cognitive impairment from those with normal cognition. The aim of this study was to establish the validity, reliability, and discriminative properties of the Korean version of the AD8 (K-AD8). Evaluation was made on 155 patient-informant dyads. […]

Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients

Unlabelled: The availability of new PET ligands offers the potential to measure fibrillar β-amyloid in the brain. Nevertheless, physiologic information in the form of perfusion or metabolism may still be useful in differentiating causes of dementia during life. In this study, we investigated whether early (11)C-Pittsburgh compound B ((11)C-PIB) PET frames (perfusion (11)C-PIB [pPIB]) could […]

Malnutrition in community-dwelling adults with dementia (NutriAlz Trial)

Objectives: The objective of this study is to assess the nutritional status, measured by the MNA, in community-dwelling elderly individuals with dementia and to identify clinical risk factors for nutritional risk or malnutrition.; Design: Cross-sectional analysis of a cluster randomized clinical trial (Nutrialz).; Setting: Community-dwelling individuals attending dementia clinics.; Participants: 940 individuals.; Measurements: The clinical […]

Patterns of cognitive decline, conversion rates, and predictive validity for 3 models of MCI

Our objective was to compare the predictive ability of different models of mild cognitive impairment (MCI) as a marker of incipient dementia in a longitudinal population-based Canadian sample. We examined the use of existing, well-documented MCI criteria using data from persons who underwent a clinical examination in the second wave of the Canadian Study of […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: